MAPT and Alzheimer disease: Both the National Institute on Aging and Alzheimer's Association (NIA-AA; 2011) and the International Working Group (IWG-2; 2014) have proposed using tau protein and p-tau protein levels in cerebrospinal fluid as a diagnostic biomarker of AD [5].